331245-88-6

Upstream product

• 138526-69-9 3,4,5-trifluoro-1-bromobenzene 
• 141-82-2 malonic acid 
• 132123-54-7 3,4,5-trifluorobenzaldehyde 

Downstream Products

• 1610374-07-6 benzyl (3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-ylcarbamate 
• 1610374-06-5 (3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxylic acid 
• 1610374-05-4 (R)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one 
• 1610374-04-3 (R,E)-4-phenyl-3-(3-(3,4,5-trifluorophenyl)acryloyl)oxazolidin-2-one 
• 1609084-41-4 (E)-N-(2,3-dimethoxy-5-(3,4,5-trimethoxybenzoyl)phenyl)-3-(3,4,5-trifluorophenyl)acrylamide 

Relevant academic research and scientific papers

Synthesis and mesomorphic properties of tolane-based fluorinated liquid crystals with an acrylate linkage

Six series of tolane-based fluorinated liquid crystals containing an acrylate linker were synthesized and their mesomorphic properties were characterized. The compounds generally exhibit SmA and N phases in wide temperature ranges. The introduction of acrylate linkers increases the clearing points by 20°C-30°C and suppresses the formation of higher ordered monotropic SmB phases. para-Fluorination is favorable for the mesophase stability, whereas meta-fluorination is not. The introduction of a 2,3,5,6-tetrafluorophenylene group decreases the clearing points and also suppresses the formation of the monotropic SmB phase. Copyright Taylor & Francis Group, LLC.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.